Insmed Incorporated (NASDAQ:INSM) Shares Sold by Bellevue Group AG

Bellevue Group AG decreased its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 6.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,141,843 shares of the biopharmaceutical company’s stock after selling 149,115 shares during the period. Bellevue Group AG owned approximately 1.44% of Insmed worth $58,108,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC bought a new stake in Insmed in the fourth quarter worth $25,000. EntryPoint Capital LLC bought a new stake in Insmed in the first quarter valued at about $33,000. Fidelis Capital Partners LLC bought a new position in shares of Insmed during the 1st quarter worth approximately $34,000. Headlands Technologies LLC bought a new stake in shares of Insmed in the 1st quarter worth about $59,000. Finally, Quarry LP acquired a new position in Insmed in the fourth quarter valued at about $116,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Mizuho lifted their price target on Insmed from $36.00 to $82.00 and gave the company a “buy” rating in a report on Friday, June 7th. Morgan Stanley increased their price target on shares of Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, July 12th. HC Wainwright boosted their price objective on shares of Insmed from $70.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. The Goldman Sachs Group boosted their price objective on shares of Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. Finally, UBS Group lifted their target price on Insmed from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, May 29th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.50.

Insider Buying and Selling at Insmed

In other Insmed news, insider John Drayton Wise sold 5,088 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $25.47, for a total value of $129,591.36. Following the transaction, the insider now directly owns 123,259 shares in the company, valued at $3,139,406.73. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider John Drayton Wise sold 5,088 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $25.47, for a total transaction of $129,591.36. Following the completion of the sale, the insider now owns 123,259 shares in the company, valued at $3,139,406.73. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 11,088 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $25.32, for a total value of $280,748.16. Following the completion of the transaction, the chief financial officer now directly owns 117,481 shares in the company, valued at approximately $2,974,618.92. The disclosure for this sale can be found here. Insiders sold 295,842 shares of company stock valued at $13,762,062 in the last quarter. 4.60% of the stock is currently owned by insiders.

Insmed Trading Up 0.1 %

Shares of Insmed stock traded up $0.04 during trading on Friday, hitting $74.54. 1,423,882 shares of the stock were exchanged, compared to its average volume of 2,531,316. Insmed Incorporated has a 1-year low of $20.33 and a 1-year high of $78.87. The stock has a market capitalization of $11.08 billion, a price-to-earnings ratio of -14.25 and a beta of 1.16. The company has a fifty day moving average price of $61.37 and a 200-day moving average price of $39.22.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.16. The business had revenue of $75.50 million during the quarter, compared to the consensus estimate of $77.76 million. During the same quarter in the prior year, the company earned ($1.17) EPS. Insmed’s quarterly revenue was up 15.8% on a year-over-year basis. Equities research analysts forecast that Insmed Incorporated will post -4.71 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.